Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.57 |
| ▸ | CES1 | P23141 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 2/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.54 |
| ▸ | MGLL | Q99685 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16432038 | 0.98 | HTR2C (0.57) | CES2CES1HTR2CHSD11B1MGLL | |
| SCHEMBL7309424 | 0.90 | CES2 (0.65) | CES2CES1HSD11B1MGLLPARP1 | |
| SCHEMBL31636008 | 0.90 | CES2 (0.65) | CES2CES1HSD11B1MGLLPARP1 | |
| Tert-Butyl Formate SCHEMBL27968800 | 0.88 | HTR2C (0.46) | CES2CES1HTR2CHSD11B1MGLL | |
| SCHEMBL18360283 | 0.87 | KDM2B (0.62) | CES2CES1HSD11B1MGLLPARP1 | |
| SCHEMBL4772361 | 0.84 | KDM2B (0.54) | CES2CES1HSD11B1MGLLPARP1 | |
| SCHEMBL230405 | 0.84 | NPC1 (0.71) | HSD11B1MGLLMEN1KMT2ACYP2D6 | |
| Hydrochloric Acid SCHEMBL17913736 | 0.83 | KDM2B (0.53) | CES2CES1HSD11B1MGLLPARP1 | |
| SCHEMBL18851107 | 0.83 | KMT2A (0.53) | MEN1KMT2ACYP2D6RAB9A | |
| Bromide SCHEMBL7247705 | 0.83 | NPC1 (0.69) | HSD11B1MGLLMEN1KMT2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9901577-B2 | Oxoquinazolinyl-butanamide derivatives | MERCK PATENT GMBH (DE) | 2018-02-27 | — | — | US | disclosed |
| US-9901577-B2 | Oxoquinazolinyl-butanamide derivatives | MERCK PATENT GMBH (DE) | 2018-02-27 | — | — | US | disclosed |
| EP-3027598-B1 | OXOQUINAZOLINYL-BUTANAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-04-12 | — | — | EP | disclosed |
| US-20160184310-A1 | OXOQUINAZOLINYL-BUTANAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-06-30 | — | — | US | disclosed |
| US-20160184310-A1 | OXOQUINAZOLINYL-BUTANAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-06-30 | — | — | US | disclosed |
| WO-2015014442-A1 | OXOQUINAZOLINYL-BUTANAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-02-05 | — | — | WO | disclosed |
| CN-1723199-A | 1,4-disubstituted piperidine derivatives and their use as 11-beta hsd1 inhibitors | ASTRAZENECA AB (SE) | 2006-01-18 | — | — | CN | disclosed |
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| EP-1556349-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | Astrazeneca AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004033427-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | WO | disclosed |
| EP-0971926-A1 | DIHYDROPYRAZINO 1,2-$i(A)-]INDOLE-1-ONE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS | SANOFI-SYNTHELABO (FR) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998042710-A1 | DIHYDROPYRAZINO [1,2-A-]INDOLE-1-ONE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS | SANOFI-SYNTHELABO (FR) | 1998-10-01 | — | — | WO | disclosed |
| US-4341893-A | HYPOTENSIVE AGENTS | SYNTHELABO (FR) | 1982-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184310-A1 | OXOQUINAZOLINYL-BUTANAMIDE DERIVATIVES | TANK, IRAK3, TNKS | CES2 2831/4885CES1 310/4885HTR2C 4050/4885 |
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | HSD11B1, HSD3B1, P4HA1 | CES2 419/4885CES1 50/4885HTR2C 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.